Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans

Journal of Nuclear Medicine

Volumn 53, Issue 5, 2012, Pages 787-795

  Doss, Mohan ^a   Kolb, Hartmuth C ^b   Zhang, James J ^b   Bélanger, Marie José ^c   Stubbs, James B ^d   Stabin, Michael G ^e   Hostetler, Eric D ^c   Alpaugh, R Katherine ^a   Von Mehren, Margaret ^a   Walsh, Joseph C ^b   Haka, Michael ^b   Mocharla, Vani P ^b   Yu, Jian Q ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b SIEMENS CORPORATE RESEARCH   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Radiation Dosimetry Systems Inc   (United States)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

18F RGD K5; Biodistribution; Integrin marker; Internal dosimetry; PET

Indexed keywords

2 ( 5 BENZYL 8 (4 ( 6 ((2 (4 (3 FLUOROPROPYL) 1H 1,2,3 TRIAZOL 1 YL)ACETAMIDO)METHYL) 3,4,5 TRIHYDROXYTETRAHYDRO 2H PYRAN 2 CARBOXAMIDO)BUTYL) 11 (3 GUANIDINOPROPYL) 3,6,9,12,15 PENTAOXO 1,4,7,10,13 PENTAAZACYCLOPENTADECAN 2 YL)ACETIC ACID F 18; IOHEXOL; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ADULT; AGED; ARTICLE; BLADDER; BLOOD SAMPLING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER PROGRAM; DOSE RESPONSE; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG UPTAKE; DRUG URINE LEVEL; FEMALE; GALLBLADDER; HUMAN; HUMAN EXPERIMENT; KIDNEY; KIDNEY CLEARANCE; LIVER; MALE; MICTURITION; NONHUMAN; NORMAL HUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION ABSORPTION; RHESUS MONKEY; WHOLE BODY SCINTISCANNING;

ADULT; AGED; ANIMALS; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; MACACA MULATTA; MALE; MIDDLE AGED; OLIGOPEPTIDES; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOMETRY; WHOLE BODY IMAGING;

EID: 84860703203     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.088955     Document Type: Article

References (17)

1. Brown AP, Citrin DE, Camphausen KA. Clinical biomarkers of angiogenesis inhibition. Cancer Metastasis Rev. 2008;27:415-434.
2. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
3. Gasparini G, Brooks PC, Biganzoli E, et al. Vascular integrin avb3: A new prognostic indicator in breast cancer. Clin Cancer Res. 1998;4:2625-2634. (Pubitemid 28523488)
4. Vonlaufen A, Wiedle G, Borisch B, Birrer S, Luder P, Imhof BA. Integrin avb3 expression in colon carcinoma correlates with survival. Mod Pathol. 2001; 14:1126-1132.
5. Beer AJ, Haubner R, Wolf I, et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging avb3 expression. J Nucl Med. 2006;47: 763-769. (Pubitemid 46768438)
6. Haubner R, Kuhnast B, Mang C, et al. [18F]Galacto-RGD: Synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004; 15:61-69. (Pubitemid 38165981)
7. Walsh JC, Kolb HC. Applications of click chemistry in radiopharmaceutical development. Chimia (Aarau). 2010;64:29-33.
8. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027. (Pubitemid 43733519)
9. Barrett PH, Bell BM, Cobelli C, et al. SAAM II: Simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47:484-492. (Pubitemid 28180958)
10. Cloutier RJ, Smith SA, Watson EE, Snyder WS, Warner GG. Dose to the fetus from radionuclides in the bladder. Health Phys. 1973;25:147-161.
11. International Commission on Radiological Protection (ICRP). Limits of intake of radio-nuclides by workers. Publication 30. Ann ICRP. 1979;2.
12. Food and Drug Administration (FDA). Guidance for Industry and Researchers, The Radioactive Drug Research Committee: Human ResearchWithout an Investigational New Drug Application. August 2010. Available at: Http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM163892.pdf. Accessed April 2, 2012.
13. Herzog H, Elmenhorst D, Winz O, Bauer A. Biodistribution and radiation dosimetry of the A1 adenosine receptor ligand 18F-CPFPX determined from human whole-body PET. Eur J Nucl Med Mol Imaging. 2008;35:1499-1506.
14. Stabin M, Stubbs J, Toohey R. Radiation dose estimates for radiopharmaceuticals, NUREG/CR-6345. April 1996. Available at: Http://www.nrc.gov/reading-rm/doccollections/nuregs/contract/cr6345/cr6345.pdf. Accessed April 2, 2012.
15. Doss M, Zhang JJ, Belanger MJ, et al. Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and humans determined by using whole-body PET/CT. Nucl Med Commun. 2010;31:1016-1024.
16. Graham MM, Peterson LM, Link JM, et al. Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. J Nucl Med. 1997;38:1631-1636. (Pubitemid 27443967)
17. Tolvanen T, Lehtio K, Kulmala J, et al. 18F-Fluoroerythronitroimidazole radiation dosimetry in cancer studies. J Nucl Med. 2002;43:1674-1680. (Pubitemid 35424994)